According to the current European Society of Cardiology guidelines, it is mandatory to initially assess the risk of early death based on clinical and hemodynamic criteria to determine management strategy. 4 Depending on estimated patients' mortality risk, a variety of therapeutic approaches are now INTRODUCTION Pulmonary embolism (PE) is one of the most common cardiovascular diseases, with an estimated global incidence rate of 39 to 115 per 100 000 person-years. 1,2 Pulmonary embolism may be life-threatening with an estimated 30-day mortality rate of 10% to 30%.

No abstract

No abstract

No abstract

Basiliximab administration as induction therapy, tacrolimus serum concentration, and duration of intensive care unit stay are risk factors for leucopenia.